Argenx advances clinical development of efgartigimod in primary sjogren's disease

Rho study supports proof-of-concept in primary sjogren's disease decision informed by favorable safety profile and consistency across efficacy and biomarker measures march 27, 2024, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to phase 3 in adults with primary sjogren's disease (sjd), following the analysis of topline data from the phase 2 rho study. detailed results will be presented at a future medical meeting.
ARGX Ratings Summary
ARGX Quant Ranking